KZA 0.00% 41.0¢ kazia therapeutics limited

Novogen - Raging buy

  1. 3,567 Posts.
    Check out todays announcement... their anti-cancer drug is working and US investors are taking note. A comment

    "Dr. Mor's team has reported that phenoxodiol is a highly effective drug that kills all ovarian cancer cells and does so by a unique mechanism that causes ovarian cancer cells to self-destruct."

    Here is the full article:

    http://biz.yahoo.com/prnews/020827/dctu007_2.html

    Press Release Source: Marshall Edwards Inc.


    Yale Researchers Reveal Phenoxodiol's Unique Ability To Kill Ovarian Cancer Cells
    Marshall Edwards Inc. and Yale University Medical School To Develop Phenoxodiol for Ovarian Cancer
    Tuesday August 27, 8:46 am ET

    WASHINGTON, Aug. 27 /PRNewswire-FirstCall/ -- Marshall Edwards Inc. (LSE-AIM: MSH), the subsidiary of pharmaceutical company, Novogen Limited (Nasdaq: NVGN - News), has entered into a services agreement with the Yale University School of Medicine's Department of Obstetrics and Gynecology.

    ADVERTISEMENT


    The association with Yale revolves around the recent discovery in Yale Medical School laboratories that MEI's anti-cancer drug, phenoxodiol, has a uniquely strong effect against ovarian cancer cells.

    Ovarian cancer is the fifth largest cause of death from cancer in women, and the American Cancer Society estimates that over 23,000 women will develop ovarian cancer in the U.S. each year. The treatment options and prognosis for women with late-stage ovarian cancer remain poor.

    In a search for an effective drug to treat ovarian cancer, the research team at Yale University Medical School, headed by Gil Mor M.D. Ph.D., has been screening new anti-cancer drugs for their ability to kill ovarian cancer cells, and in particular, to switch off a mechanism on which ovarian cancer cells depend for survival.

    Dr. Mor's team has reported that phenoxodiol is a highly effective drug that kills all ovarian cancer cells and does so by a unique mechanism that causes ovarian cancer cells to self-destruct.

    One of the outcomes of the Yale association will be to arrange a phase II clinical trial in patients with advanced ovarian cancer at Yale under the direction of Dr. Thomas Rutherford. This will be a multi-center trial to be conducted in conjunction with an Australian university hospital.

    Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials. After the results of these trials are submitted in a new drug application to the FDA, the FDA must approve the drug as safe and effective before marketing can take place.

    MEI, which trades on the Alternative Investment Market of the London Stock Exchange, is 95 percent owned by Novogen Limited. MEI was established to provide a commercial vehicle for Novogen's anti-cancer drug technology, the first of which is the novel anti-cancer drug phenoxodiol.

    Novogen is a pharmaceutical company based in Sydney, Australia with offices in Stamford, Connecticut. More information on phenoxodiol can be found at http://www.novogen.com and http://www.marshalledwardsinc.com.

    Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in the Company's Securities and Exchange Commission filings under "Risk Factors," including risks relating to the early stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

    FOR FURTHER US: DAVID SHEON TELEPHONE: +1 202 518 6384
    INFORMATION: AUSTRALIA: DR. GRAHAM KELLY TELEPHONE: +612 8877 6196





    --------------------------------------------------------------------------------
    Source: Marshall Edwards Inc.

    Email this story - Set a News Alert

    ADVERTISEMENTSpecial Offers
    · Paying too much for car insurance? Find out
    · Rent all the DVDs you want - Try FREE!
    · Interest rates won't stay this low forever. Yahoo! Mortgage Center
    · Planning to Sell Your Home? Compare REALTORS® Now!




    Related Quote
    NVGN 4.599 +1.149 News
    View Detailed Quote
    Delayed 20 mins
    Quote data provided by Reuters


    Related News Stories
    · Novagen Unit, Yale University In Services Pact - Dow Jones Business News (Tue Aug 27)
    · Two Newly Published Studies Confirm Promensil Reduces Frequency, Severity of Hot Flashes - PR Newswire (Tue Aug 13)
    · Marshall Edwards, Inc. and the National Institutes of Health Join Forces To Study the Investigational Anti-Cancer Drug, Phenoxodiol - PR Newswire (Wed Jul 24)
    · Clinical Study Confirms that Red Clover Isoflavones Help Maintain Healthy Cholesterol in Menopausal Women - PR Newswire (Mon Jun 17)
    More...

    --------------------------------------------------------------------------------

    · By industry: Education, Health care, Medical/pharmaceutical



    Top Stories
    · Ex-WorldCom's Execs Got Big IPO Shares - Reuters Business Report (12:16 am)
    · Stocks Sag on Worries Consumer Won't Spend - Reuters Business Report (Tue Aug 27)
    · Durable Orders Up, Consumer Confidence Off - Reuters Business Report (Tue Aug 27)
    · Retail Sales Slip as Rebound Looks Shaky - Reuters Business Report (Tue Aug 27)
    More...

    --------------------------------------------------------------------------------

    · Most-emailed articles
    · Most-viewed articles



    Finance Spotlight
    · Research Reports
    Expert insight at great prices
    · MarketTracker
    Live streaming quotes for $9.95/mo




 
watchlist Created with Sketch. Add KZA (ASX) to my watchlist
(20min delay)
Last
41.0¢
Change
0.000(0.00%)
Mkt cap ! $29.58M
Open High Low Value Volume
41.5¢ 41.5¢ 40.0¢ $81.05K 198.3K

Buyers (Bids)

No. Vol. Price($)
1 100000 40.0¢
 

Sellers (Offers)

Price($) Vol. No.
41.5¢ 28799 2
View Market Depth
Last trade - 15.58pm 14/11/2019 (20 minute delay) ?
(live)
Last
41.0¢
  Change
0.000 ( 0.00 %)
Open High Low Volume
41.0¢ 41.0¢ 40.0¢ 27411
Last updated 15.58pm 14/11/2019 (live) ?
KZA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.